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Abstract
Background: For the targeted therapy of solid tumor mediated by monoclonal antibody (mAb),
there have different models of rebuilding small antibodies originated from native ones. Almost all
natural antibody molecules have the similar structure and conformation, but those rebuilt small
antibodies cannot completely keep the original traits of parental antibodies, especially the reduced
specificity, which gravely influences the efficacy of small antibodies.
Methods: In this study, authors developed a novel mimetic in the form of VHFR1C-10-VHCDR1-
VHFR2-VLCDR3-VLFR4N-10for a parental mAb induced with human breast cancer, and the mimetic
moiety was conjugated to the C-terminal of toxicin colicin Ia. The novel fusion peptide, named
protomimecin (PMN), was administered to MCF-7 breast cancer cells to demonstrate its killing
competency in vitro and in vivo.
Results: Compared with original antibody-colicin Ia (Fab-Ia) and single-chain antibody-colicin Ia
(Sc-Ia) fusion proteins, PMN retained the targeting specificity of parental antibody and could
specifically kill MCF-7 cells in vitro. By injecting intraperitoneally into BALB/c athymic mice bearing
MCF-7 tumors, with reduced affinity, PMN significantly suppressed the growth of tumors compared
with control mice treated by toxicin protein, Fab-Ia protein, Sc-Ia protein or by PBS (p < 0.05).
Conclusion: This novel mimetic antibody retained original specificity of parental antibody, and
could effectively guide killer moiety to suppress the growth of breast cancer by targeted cell death.
Background
Targeted therapy with maximal effectiveness and minimal
adverse effects is the ultimate goal for treatment of solid
tumors [1,2]. Since the development of hybridoma and
monoclonal antibody (mAb) technology [3,4], antibody
therapy has emerged as the choice for targeted therapy for
solid tumors because of the specific affinity of the anti-
body for the corresponding antigen, owing to the pres-
ence of six complementarity-determining regions (CDRs)
in the variable domains of the heavy chain (VH) and that
of light chain (VL) [3,5]. However, although native anti-
bodies have the highest specificity and affinity for anti-
gens, they also have large molecular structures and the
potency of penetrating into the core area of solid tumors
cannot reach to the extent that scientists expect because of
the "binding barrier"[6]. Single-chain Fvs (scFvs) contain
the specificity of the parental antibody molecules, but
they readily form aggregations [7]. Overlooking the syner-
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gistic antigen recognition relationship between VH and VL,
artificially rebuilt single-domain antibodies or micro-anti-
bodies cannot completely keep the specificity and affinity
of parental antibody [8,9].
We proposed that the essential interface of antibody-anti-
gen binding constrained by the molecular forces between
VH and VL [10,11]. For original antibody molecules, the
constraint force derives from the 3-Dimension conforma-
tion of antibody molecules. Our small antibody was con-
structed in the following form: VHFR1C-10-VHCDR1-
VHFR2-VLCDR3-VLFR4N-10 (Fig. 1a). Antigen recognition
by intact antigen-binding fragment (Fab) of immu-
noglobulin (Ig) is synergistically produced by all six CDRs
in both VH and VL domain, CDR3 is located in the center
of the antigen-recognition interface of the parental anti-
body and should be contained within the internal portion
of the small antibody [12]. Another CDR domain selected
was VHCDR1 normally the closest to CDR3, which formed
the synergistic interface with CDR3 for antigen-recogni-
tion [8,9]. The VHFR2 segment linked the two CDRs and
contains the least hydrophobic amino acid (aa) residues,
increasing the water solubility of the mimetic complex.
Finally, VLFR4N-10 and VHFR2 supported CDR3 to form
the projected loop conformation, and the VHCDR1 loop
was restrained on both sides by VHFR2 and VHFR1C-10
forming the other loop conformation. These selected
components of the mimetic are original and not changed
or substituted from the parental antibody. Guided by
these reasons, we proposed that the construct of mimetic
kept specificity similar to that of parental antibody (Fig.
1a).
In the present study, we constructed the small antibody
consisting of VHFR1C10-VHCDR1-VHFR2-VLCDR3-
VLFR4N10 conjugated in-line, as a mimetic molecule for a
natural monoclonal IgG against human breast cancer cell
envelope antigen c-erbB-2 [13,14]. The mimetic was then
conjugated to the C-terminal of colicin Ia, a 70-kD mem-
ber of the E1 colicin family of channel-forming bacterioc-
ins that are bactericidal to Escherichia coli (E. coli) to obtain
a fusion protein, named protomimecin (PMN; Fig. 1b, c),
which enable us to demonstrate the ability of the mimetic
to target cancer cells bearing specific surface antigens. Col-
icin Ia kills target cells by forming a voltage-activated
channel in the cell membrane of target cells mediated by
its C-terminal 175-residues, channel-forming domain
which contains the killing competency of "one molecule,
one kill" [15,16]. We demonstrated that PMN could effec-
tively kill MCF-7 cells in vitro and suppress the growth of
MCF-7 tumors in vivo. Based on our preliminary results,
this novel model of reconstructing small antibodies may
be further developed for targeted therapy of tumors.
Methods
Cell lines and cell culture
The hybridoma cell line HB-8696 was purchased from
ATCC and grown in Dulbecco's modified Eagle Medium
(DMEM) and fortified with penicillin-streptomycin (100
U/ml, 100 μg/ml respectively) and 10% fetal bovine
serum (FBS). Medium was changed every 2–3 days. The
breast cancer cell lines, Zr-75-30 and MCF-7, and the
Burkitt's Lymphoma cell line, Raji (obtained from the
Laboratory of Transplant Immunology and the Depart-
ment of Laboratory Medicine, Division of Clinical Immu-
nology, West China Hospital) were grown in RPMI 1640
medium containing double antibiotics and 10% FBS.
Medium was changed every 2–3 days. All cell lines were
incubated at 37°C in 5% CO2 incubator (Sanyo Electro.
Biomed. Japan).
The preparation of parental antibody 520C5 and toxicin 
colicin Ia
HB-8696 murine hybridoma cells were grown to a density
of 107 cells/ml. Under sterility and 4°C, the cells were
removed from the medium by centrifugation at 1000
Schematic diagram for the process of constructing the small antibody and the fusion peptide Figure 1
Schematic diagram for the process of constructing the small antibody and the fusion peptide. (a) The small anti-
body (the mimetic moiety) was composed of VHFR1C-10-VHCDR1-VHFR2-VLCDR3-VLFR4N-10. (b, c) The mimetic was 
conjugated to the C-terminal of wild-type colicin Ia to construct the conjugated peptide, named protomimecin (PMN). (d) The 
15% SDS- PAGE migration map of the fusion peptide PMN.Journal of Experimental & Clinical Cancer Research 2009, 28:59 http://www.jeccr.com/content/28/1/59
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rpm, and the supernatant (containing the original mAbs
520C9 that are the parental antibody of the mimetic pep-
tide molecules) was further purified by centrifugation at
10,000 g. The following purification procedure was done
according to purification kit' protocol (Millipore). The
purified antibodies were stored at -20°C for subsequent
experiments.
The pSELECT-1 plasmids (from the Key Laboratory of Trans-
plant Engineering and Immunology, Ministry of Health,
West China Hospital, Sichuan University, China) that
contain the colicin Ia gene and the reversed direction
immunity protein gene of colicin Ia were transformed
into competent TG1 cells. Then spread those TG1 cells on
FB agar medium containing 25 μg/ml ampicillin and cul-
tivated at 37°C for 12–16 hours under humidity and
screening TG1 cells containing pSELECT-1 plasmids, and the
positive clones were selected to cultivate rotatorily at 180
rpm in 2 ml FB medium containing 50 μg/ml ampicillin
under the same condition as above mentioned for over-
night, then carefully dumped to 60 ml FB medium for
continuous cultivation for 5–6 hours. Until the total vol-
ume of medium reached 8 × 600 ml and the OD for TG1
cells reached 0.5 under same culture condition, centri-
fuged those cells at 6,000 g for 17 minutes under 4°C, and
resuspended precipitate in 60–80 ml borate buffer (50
mM borate buffer, pH 9.0, with 2 mM EDTA) containing
0.5 mM phenylmethylsulfonyl fluoride. The cells were
sonicated and debris removed by centrifugation for 90
min at 75,000 g under 4°C. Nucleic acids were precipi-
tated by addition of 1/5 volume streptomycin sulfate
(25%). Supernatants were dialyzed against borate buffer
for 12 hours (changing the buffer every 5–6 hours) at 4°C
then applied to the ÄKTA™ prime protein purification sys-
tem (2.5 × 12 cm CM-Sepharose column, Amersham
Pharmacia Biocech). Proteins were recovered at 4°C by
gradient elution with 0.1, 0.2 and 0.3 M NaCl in borate
buffer and collected in 0.5 ml fractions. The harvested col-
icin Ia was dialyzed against PBS (pH 7.4–7.5) for 12 hours
at 4°C, and stored at -80°C freezer for subsequent exper-
iments.
The scanning of VH and VL domain DNA sequences of 
original antibody
VH and VL domain genes for mAb A520C9 IgG were iso-
lated from HB-8696 mouse hybridoma cell. Total RNA
was extracted and amplified by RT-PCR (Takara RNA PCR
Kit (AMV Ver.3.0)) using the following primers: H-chain:
5'-ACTAGTCGACATGGCTGTCYTRGBGCTGYTCY TCTG-
3'and 5'-CCCAAGCTTCCAGGGRCCARKGGATARACW-
GRTGG-3';  L-chain: 5'-GGGAATTCATGGAGACAGACA
CACTCCTGCTAT-3'and 5'-CCCAAGCTTACTGGA TGGT-
GGGAAGATGGA-3', purified RT-PCR products were
ligated into the plasmids pMD18-T, purchased from
Takara. The DNA sequences of plasmids were isolated and
analyzed to determine the genes of VH and VL domains of
mAb.
Amino acid sequences of peptides from parental antibody
The aa sequences of all six CDRs in the parental antibody
520C9 Fab are:
VH: H2N-EMQLVESGPEVKKPGASVKVSCKASGYTFT-
NYGMNWVRQAPGQGLEWM GWINTYTGQSTYAD
DFKERVTMTTDTSTSTAYDMLRSLRSDDTAVYYCAR-
RFGFAYWQ GTLVVSS-COOH (bold letters represent
CDR domain)
VL:H2N-DIQMTQSPSSLSASVGDRVTITCRASQDIGN
SLTWYQQKPGKTPKLLIYATS SLDSGVPSRFSGSGSG
TDFTFTISSLQPEDIATYYCLQYAIFPYTFGQGTRLEIK-
COOH (bold letters represent CDR domain)
The sequence of the single-chain Fv (ScFv) for the parental
antibody 520C9 is:
VH-(GGGGS)3-VL [17]
The sequence of the VHFR1C-10-VHCDR1-VHFR2-VLCDR3-
VLFR4N-10mimetic of the parental antibody is:
H2N-SCKASGYTFTNYGMNWVRQAPGQGLEWMGL
QYAIFPYTFGQGTRLEIK-COOH
Preparation of the mimetic moiety and conjugated 
peptide
The DNA sequences for the VHFR1C-10, VHCDR1, VHFR2,
VLCDR3 and VLFR4N-10 regions of the 520C9 Fab were
conjugated to follow position I626 of colicin Ia by dou-
ble-stranded oligonucleotide mutagenesis (QuickChange
kit, Stratagene) using the pSELECT-1 plasmid that contains
the colicin Ia gene and the reversed direction immunity
protein gene of colicin Ia to form colicin Ia-VHFR1C-10-
VHCDR1-VHFR2-VLCDR3-VLFR4N-10 (Fig. 1). The oligonu-
cleotides used contained the desired mutations for SCK-
ASGYTFTNYGMNWVRQAPGQGLEWMGLQYAI FPYTFG
QGTRLEIK were 5'-GCG AAT AAG TTC TGG GGT ATT
TCC TGC AAG GCT TCT GGT TAC ACC TTT ACC TAA
ATA AAA TAT AAG ACA GGC-3', 5'-GCT TCT GGT TAC
ACC TTT ACC AAC TAT GGA ATG AAC TGG GTG CGA
CAG GCC TAA ATA AAA TAT AAG ACA GGC-3', 5'-ATG
AAC TGG GTG CGA CAG GCC CCT GGA CAA GGG CTT
GAG TGG ATG GGA CTA TAA ATA AAA TAT AAG ACA
GGC-3', 5'-GGG CTT GAG TGG ATG GGA CTA CAA TAT
GCT ATT TTT CCG TAC ACG TTC GGC TAA ATA AAA
TAT AAG ACA GGC-3' and 5'-ATT TTT CCG TAC ACG TTC
GGC CAA GGG ACA CGA CTG GAG ATT AAA TAA ATA
AAA TAT AAG ACA GGC-3' (boldface triplets represent
inserted sites).Journal of Experimental & Clinical Cancer Research 2009, 28:59 http://www.jeccr.com/content/28/1/59
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Plasmids containing inserted DNA sequences were trans-
formed into competent TG1 E. coli, and cells were grown
in FB medium containing 50 μg/ml ampicillin. The proce-
dures of cultivating TG1 cells and purifying conjugated
peptides were the same as that of preparing colicin Ia pro-
tein.
In vitro killing activity, Immunolabeling and affinity assays
ZR-75-30, MCF-7, and Raji cells were grown in the Falcon
3046 six-well cell culture plates (Becton Dickinson Co.)
under the same condition as that of above described. 24
hours later, 5–125 μg/ml PMN, wild type colicin Ia (wt
Ia), parental antibody-colicin Ia fusion protein (Fab-Ia),
single-chain antibody-colicin Ia fusion protein (Sc-Ia)
(CL(Xi'an) Bio-scientific) and nonrelative control protein,
low molecular weight marker protein (LWMP, purchased
from Takara) were respectively added to the cell culture
wells. After co-incubating for 24 hours, the living and
dead cells were stained with 50 nM acridine orange and
600 nM propidium iodide and staining was imaged using
a digital data collection system under an inverted fluores-
cent microscope (IX-71, Olympus) using U-MWU2, U-
MNB2 and U-MNG2 filters. For the comparison of killing
competency presented by those agents with each other, we
selected five image fields to respectively count the number
of dead and living cells in every culture well after 24, 48
and 72 hours.
MCF-7 cell were grown in 1640 medium for 72 h, fixed in
10% paraformaldehyde for 40 min at room temperature,
then 100 μl fixed cells (106/ml) were incubated with 10 μl
PBS, LWMP, Fab, Sc (CL(Xi'an) Bio-Scientific) and PMN
respectively with different concentration (102-10-1nM) for
1 hr at 37°C, then incubated with parental antibody for
40 min at 37°C and fluorescein isothiocyanate (FITC) -
labeled second antibody (Pierce) for 30 min at 37°C.
After incubating with DAPI for 25 minutes at 37°C, the
mean fluorescent intensity of per 1,500 cells was meas-
ured by BD FACSCanto Flow Cytometer (BD Biosciences).
For concentration-dependent inhibitory experiments
against the killing activity of PMN, different concentra-
tions of either parental A520C9 mAbs, or synthetic
VHFR1C-10-VHCDR1-VHFR2-VLCDR3-VLFR4N-10  (South
West University) were added with PMN (75 μg/ml) to
incubate with MCF-7, Zr-75-30 or Raji cells, respectively
(102-10-1nM), then living and dead cells were counted
with 0.2% Trypan blue under an inverted microscope (IX-
71, Olympus).
The MCF-7 cells were grown and fixed as the above-men-
tioned procedure. Then original antibodies (OAbs) and
the mimetic peptides were diluted to 100, 10, 1 and 0.1
μmol/L by PBS (pH7.45), respectively. The indirect
enzyme-linked immunosorbent assays (ELISA) were
introduced to analysis the relative affinity of the mimetics
and OAbs to antigens. The value of absorbance at 490 nm
wavelength was inspected by microplate reader (Bio-Rad),
which was used to determine the concentration of the
OAbs and the mimetics when the saturation of Abs to
antigens reached to one percent. The relative affinity was
compared between OAbs and the mimetics at 50% satura-
tion of Abs to antigens.
In vivo activity and the biodistribution of PMN
MCF-7 cells were grown under the same condition as that
of above described, and collected by centrifugation at
1,000 rpm. Cells were resuspended in FBS-free medium at
a concentration of 108 cells/ml. Twenty-five 4–5-week-old
female BALB/c athymic nude mice weighing 16–20 g were
purchased from the Experimental Animal Center of West
China Hospital. Before implanting tumor cells, mice were
allowed to acclimatize for 3 days. A total of 6–7 × 107
MCF-7 cells were subcutaneously (s.c.) implanted into the
left armpit of mice. Tumor growth was monitored daily
until the average sizes of tumors reached 5 × 5 × 5 mm,
then randomly separated those mice to the treatment
group (PMN group; n = 5), wild type colicin Ia group (wt
Ia group; n = 5), Fab-Ia group (n = 5), Sc-Ia group (n = 5)
and the PBS control group (PBS group; n = 5), and the
treatment course began. The PMN group was treated with
intraperitoneal (i.p.) injection of PMN at 1,200 μg/
mouse/day (400 μg/8 hours, tid; n = 5). The wt Ia group,
Fab-Ia group, Sc-Ia group and the PBS group were injected
with wt Ia protein, Fab-Ia protein, Sc-Ia protein (400 μg/8
hours, i.p. tid; n = 5) and PBS (450 μl/8 hours, i.p. tid; n
= 5), respectively. Animals had free access to standard
food and water throughout the treatment course. After 14
days, all mice were sacrificed to collect tumors and organs
for weighing and for histopathological inspection.
150 μg PMN proteins labeled by FITC (EZ-labeled FITC
protein labeling kit, pierce) were ip injected into BALB/c
mice (n = 5), weighing 16–20 g, inoculated MCF-7 cells at
armpit for 2 weeks. 2.5 hours later, the mice were fastened
supinely on a black board under ether inhalation. When
the in vivo inspections completed, the mice were sacrificed
and the tumors and vital organs were sectioned. The
images were observed with the LT-99D2 Illumatool Dual
Light System (excitation 470 nm, emission 515 nm,
Lightool Research) and recorded by a built-in camera.
Assessment of toxicity of PMN
Kunming normal mice (purchased from Experimental
Animal Center of West China Hospital, Sichuan Univer-
sity, China), weighing 15–25 g were injected with either
PMN (100–2,500 μg/mouse/day, n = 5) or PBS (n = 5)
intraperitoneally each day. After 3 weeks of administra-
tion, mice were sacrificed for histopathological inspection
and blood samples were collected for indirect enzyme-
linked immunosorbent assay (ELISA) to screen potential
antibodies.Journal of Experimental & Clinical Cancer Research 2009, 28:59 http://www.jeccr.com/content/28/1/59
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The Institutional Animal Care and Use Committee of
Sichuan University and Project of Sichuan Animal Experi-
ment Committee (license 045) approved the animal use
and in vivo experiments.
Electrophoresis
0.9% agarose electrophoresis was applied to authenticate
the reconstructed plasmids and 15% sodium dodecyl sul-
fate polyacrylamide gel electropheresis (SDS-PAGE) was
applied to authenticate the harvested protein, respec-
tively.
Statistical analysis
SPSS version 11.0.1 for Microsoft Windows was used for
statistical analysis. Two-tailed t-tests were performed
using GraphPad Prism for Windows version 4.00. P < 0.05
was considered to be a statistically significant difference.
Results
Production and purification of PMN
Plasmids containing the colicin Ia gene and the reversed
direction immunity protein gene of wt Ia protein were
used to conjugate signal-moiety with wt Ia (Fig. 1c). We
conjugated the 48-aa residues to the C-terminal of wt Ia by
five mutation steps, with the same PCR reaction condi-
tions (95°C, 35 sec for denaturation; 53°C, 70 sec for
annealing; 68°C, 17 min for elongation; which repeated
18 times). Plasmid migration in agarose electrophoresis
(0.9%) was applied to confirm transmutated plasmid at
each step (data not shown). After the last round of PCR,
the harvested plasmid was transformed into competent
TG1 E. coli to produce the PMN protein.
PMN protein was eluted with 0.2 M NaCl borate buffer.
The original molecular weight of wt Ia is ~70 kDa and,
with the addition of the 48-aa residues (approximately 5.3
kDa), the molecular weight of PMN is ~75 kDa, which
was confirmed by SDS-PAGE migration image (Fig. 1d).
In vitro killing activity and specificity of PMN
Against MCF-7 cells, PMN molecules presented dramatic
killing competency. Compared with Fab-Ia and Sc-Ia, who
both presented obvious killing competency to MCF-7
cells, the killing competency of PMN molecule to MCF-7
cells was significantly superior to them (p < 0.05, Fig. 2a).
The killing activity of PMN presented time- and concen-
tration-dependent characteristics. Of these cells, about
70–85% of the MCF-7 cells were killed within 48–72
hours after exposure to the PMN at concentration 75 μg/
ml (p < 0.001; Fig. 2b) and 72 hours after incubating,
PMN presented no obvious killing effect on MCF-7 cells at
concentration 5 μg/ml, but killed 80% of cells at concen-
tration 75 μg/ml (Fig. 2c). Neither wt Ia protein nor the
nonrelative LWMP could kill MCF-7, Zr-75-30 and Raji
cells up to the maximal tested concentration at any time
points (125 μg/ml). 72 hours co-incubation of Zr-75-30
and Raji with Fab-Ia, Sc-Ia, PMN and LWMP peptide mol-
ecules at any concentration did not significantly affect the
viability of these cells relative to untreated control (Fig.
2a).
We assessed the antigen-recognition capabilities of PMN,
Fab, Sc-Fv, LWMP and wt Ia peptides against MCF-7 cell
by competition with the parent antibody. The results indi-
cated that the VHFR1C-10-VHCDR1-VHFR2-VLCDR3-
VLFR4N-10 mimetic had nearly the same extent effect on
blocking binding of the parent antibody as Fab and Sc-Fv
peptides (Fig. 3a). The concentration of the mimetic pep-
tides that could induce 50% saturation of antigen was
about 10~15% that of OAbs (Fig. 3b). The killing activity
of PMN molecules against MCF-7 cells could be inhibited
up to 90% by increasing concentrations of OAbs or syn-
thetic VHFR1C-10-VHCDR1-VHFR2-VLCDR3-VLFR4N-10
mimetic molecules (Fig. 3c, d).
In vivo activity and the biodistribution of PMN
PMN, Fab-Ia and Sc-Ia agents were administered to
tumor-bearing BALB/c nude mice at 1,200 μg/mouse/day
(400  μg/8 hours, i.p. tid). Compared with the control
groups treated by PBS, wt Ia, Fab-Ia and Sc-Ia agents, PMN
effectively suppressed the growth of MCF-7 tumors in vivo
(Fig. 4a). At the end of the consecutive 14-day treatment,
the total tumor weight was significantly low in the PMN
treatment group by about 45% compared with the other
control groups (p < 0.05; Fig. 4b).
The fluorescence images revealed the targeting accumula-
tion in MCF-7 tumor location within 2.5 hours after intra-
peritoneal injection (Fig. 4c). There were no same extent
accumulations found in other vital organs except the
intestine (Fig. 4d).
The bio-safe assessment of PMN
Those immunocompromised mice bearing tumors and
those normal Kunming mice both treated by PMN
remained health and gained body weight during the
experimental course. Indirect ELISA found no detectable
antibodies against respective epitopes in normal mice
after 3 weeks treatment with different concentration PMN.
The histopathological detection found no microscopic
evidences of necrosis, inflammation or lymphocyte infil-
tration in the livers, spleens, kidneys and intestines from
normal mice (data not shown).
Histopathological analysis
We found numerous fibrous foci in tumors from the
PMN-treated group (Fig. 5b), which were not observed in
the control groups' tumors (Fig. 5a). No microscopic evi-
dence of metastasis, necrosis, inflammation or lym-
phocyte infiltration was detected in the livers, spleens,Journal of Experimental & Clinical Cancer Research 2009, 28:59 http://www.jeccr.com/content/28/1/59
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kidneys and intestines from BALB/c mice (data not
shown).
Discussion
In this study, we introduced a new model of reconstruct-
ing small antibody for targeted therapy of solid tumors,
considering that the proper CDRs loops could not auto-
matically form in the medium without the constraint
force, which made the working conformation for the anti-
gen-antibody interaction could not maintained [18]. We
added two frameworks without any residue substitutions
from original ones to both ends of two selected CDRs to
restrain their conformation for the following three rea-
sons. First, sustaining both CDRs as protruding loop struc-
tures should increase the probability of accessing target
epitopes of specific antigens [19]. Second, for the
mimetic, constraining the conformation of CDRs should
reduce the probability of forming improper conforma-
tions and increase the efficiency of antigen-recognition by
the proper conformation [8,20]. Third, the interactions
among the framework moieties of the mimetic molecules
should most effectively simulate the same kind of con-
straint force that exists among the frameworks of original
antibody molecules [8,11,20]. Guided by those reasons,
we posited that adding two restricted frameworks, with
one at each end, could further constraint the conforma-
In vitro killing activity assays of PMN Figure 2
In vitro killing activity assays of PMN. (a) Killing effects of PBS, non-relative LWMP, wt Ia, Fab-Ia, PMN and Sc-Ia on MCF-
7, Zr-75-30 and Raji cells lines. LWMP, low molecular weight marker protein; wt Ia, wild-type colicin Ia; Fab-Ia, Fab segment 
from original antibody-colicin Ia fusion peptide; PMN, protomimecin; Sc-Ia, ScFv segment from original antibody-colicin Ia 
fusion peptide. (b) MCF-7 breast cancer cells were incubated with 75 μg/ml PMN for 24, 48 and 72 hrs, respectively. And 
tumor cells were stained with acridine orange (green color) and propidium iodide (red color). Red spots, dead cell mass; 
Green spots, live cell. After co-incubation for 72 hrs, approximately 80% of all MCF-7 cells had died (upper panel). T, PMN-
treated group; C, control group treated with PBS. (c) Cytotoxicity of different concentration of PMN against MCF-7.Journal of Experimental & Clinical Cancer Research 2009, 28:59 http://www.jeccr.com/content/28/1/59
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tion of VHCDR1 and VLCDR3 loops in the mimetic. Based
on previous studies [10], we proposed that the length of
the two framework fragments should be at least 10-aa.
Therefore, the C-terminal 10-aa residues of VHFR1
(VHFR1C-10) were attached to the N-terminal of VHCDR1
and the N-terminal 10-aa residues of VLFR4 (VLFR4N-10)
were attached to the C-terminal of VLCDR3 to form
VHFR1C-10-VHCDR1-VHFR2-VLCDR3-VLFR4N-10 that could
produce the constraint force by which the proper CDR1
and CDR3 loops formed.
Our findings suggested the proper loops of VHCDR1 and
VLCDR3 were sustained in our small antibody model. The
competition test to assess inhibition of PMN binding to
specific antigens by parental antibody and synthetic
mimetic demonstrated that the mimetic model without
any substitution from original antibody contained the
specificity (Fig. 3), and the in vitro results demonstrated
this model kept the same extent specificity as Fab and ScFv
did (Fig 2a, 3a). The antigen-recognizing moiety of the
conjugated reagent could discern the specific antigens on
the breast cancer cell membrane, and guide the colicin-
derived moiety to form a transmembrane ion-channel
and ultimately killed the target cells [15]. Owing to the
absence of the specific antigen in the Raji cells, the
mimetic moiety should be unable to interact with these
cells, so they survived the lethal effects of PMN molecules
(Fig. 2a). Not only in vitro condition, but also in vivo con-
dition PMN could present its competency of recognizing
specific antigen on target cells and killing them, which
was also confirmed by our experiments finding no obvi-
ous effects on growth of MCF-7 tumor treated by wt Ia
protein (Fig. 4).
Compared to its parental antibody, this small antibody
reconstructed following the novel way kept only part
The competition ability of synthetic VHFR1C-10-VHCDR1-VHFR2-VLCDR3-VLFR4N-10 Figure 3
The competition ability of synthetic VHFR1C-10-VHCDR1-VHFR2-VLCDR3-VLFR4N-10. (a) Fixed MCF-7 cells were 
incubated with PBS, LWMP, Fab, PMN and Sc-Fv peptides (50 μM) and DAPI (50 ng/ml) prior to flow cytometry. LWMP, low 
molecular weight marker protein; Fab, Fab segment from original antibody; PMN, protomimecin; Sc-Fv, ScFv segment from 
original antibody. (b) The relative affinity of VHFR1C-10-VHCDR1-VHFR2-VLCDR3-VLFR4N-10 peptides and OAbs to antigen. 
OAb, original antibody. (c) Concentration-dependent inhibition of different concentration of synthetic mimetic antibody or 
OAb against 75 μg/ml PMN. (d) MCF-7 cell survival ratio of the inhibition activity of OAb against PMN (75 μg/ml). OAb, origi-
nal mAb antibody A520C9.Journal of Experimental & Clinical Cancer Research 2009, 28:59 http://www.jeccr.com/content/28/1/59
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affinity to antigen (Fig. 3b). And in vivo results certificated
PMN molecules could penetrate into the core area of solid
tumors. However, the increased affinity could not
improve the penetration into solid tumors [21]. Previous
studies had already confirmed that the highest affinity
scFv mainly arrested in the perivascular region of solid
tumors, whereas the lowest affinity scFv harbored the
most uniform biodistribution throughout the tumors [6].
This novel small antibody contained only 10~15% origi-
nal affinity, which assigned the mimetic increased pene-
tration and kept the specificity (Fig. 4, 5). Considering the
synthetic relationship between specificity and affinity in
the procedure of interacting of antibody to antigen
[1,2,7], under the condition of keeping original specifi-
city, maybe the reduced affinity of those rebuilt small anti-
bodies could give a more better solution to the "binding-
barrier" of solid tumors than only keeping the single spe-
cificity or affinity.
In vitro results indicated that the Fab and Sc-Fv signals
could guide the "killing moiety" to kill breast cancer cells,
but those phenomena could not be re-presented in vivo. It
was suggested that the solid tumors, especially malignant
tumors have interstitial fluid pressure in their tissues
because of the eugonic state, which prevents the diffusion
of any forms of treatment medicines into the core area of
solid tumors, especially those large peptide molecules
such as native antibody Fab and ScFv segments [22,23]. By
pathological staining, we found numerous fibrous foci in
the core area of the tumors from treated mice, which were
not inspected on tumors from the control animals includ-
ing the Fab-Ia and Sc-Ia groups (Fig. 5), indicating that
PMN molecules could efficiently penetrate into the core
area of solid tumor and kill target cells. Previous studies
on exnograft MCF-7 tumors show no evidence of metasta-
sis and no obvious fibrosis, which is consistent with our
results [24] (Fig. 5a). We observed that the parenchyma of
treated tumors presented numerous areas of embedded
fibrous tissue, indicating that the parenchyma was substi-
tuted by fibers and other connective tissue components
after necrosis (Fig. 5b). Compared with the control group
tumors, which showed much parenchyma with little
abnormal connective tissue, the pathological difference
between the tumors from PMN-treated and control
groups may be more important than just the weight differ-
ence between the groups, although the total tumor weight
difference from groups was significant (p < 0.05) after 2-
week treatment.
Furthermore, we found expression intensity of c-erbB-2
antigen was higher on Zr-75-30 than on MCF-7 cells, but
those reagents including PMN, Fab-Ia and Sc-Ia fusion
peptides produced no obvious effects on Zr-75-30 cells in
vitro (Fig. 2a), which was also found in previous studies,
showing that the same antibody conjugated to toxins or
other reagents could not always present the same killing
competency in all tested cell lines [14,15,25,26]. How-
ever, for PMN, Fab-Ia and Sc-Ia, we believed that a "bind-
ing barrier" [6], originating from intensive interactions
between the antigen and antibody, prevented the α-helix
hairpin of the channel-forming domain of colicin Ia from
approaching the plasma membrane [15,16], which
blocked the killing effect. Furthermore, the mimetic gen-
erally kept only 10~15% affinity of parental antibody to
antigen (Fig. 3b). More importantly, the c-erbB-2 mem-
In vivo killing competency and the biodistribution of PMN Figure 4
In vivo killing competency and the biodistribution of 
PMN. In vivo killing competency was compared with PBS, wt 
Ia, Fab-Ia and Sc-Ia in BALB/c athymic immunocomposed 
mice bearing MCF-7 tumors. (a) The tumors of mice were 
collected after 2-week administration. (b) The weights of 
each individual tumor were added together and the total 
weights were compared between groups. Compared with 
PBS, wt Ia, Fab-Ia and Sc-Ia, PMN could significantly suppress 
the growth of MCF-7 tumors (p < 0.05). PMN, proto-
mimecin; wt Ia, wild-type colicin Ia; Fab-Ia, Fab segment from 
original antibody-colicin Ia fusion peptide; Sc-Ia, ScFv segment 
from original antibody-colicin Ia fusion peptide. (c) Fluores-
cence images of tumor (white arrow) in BALB/c mice traced 
by FITC-labeled PMN. The green fluorescence represented 
the location of FITC-labeled PMN protein. (d) Fluorescence 
images of incised tumor and vital organs from BALB/c mice 
traced by ip injecting FITC-labeled PMN. The green fluores-
cence showed the biodistribution of FITC-labeled PMN. T, 
tumor; S, spleen; L, liver; B, brain; M, muscle; K, kidney; I, 
intestine.Journal of Experimental & Clinical Cancer Research 2009, 28:59 http://www.jeccr.com/content/28/1/59
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brane glycoprotein is a complicated antigen, and contains
different epitopes on its surface. Although almost all of
those breast cancer cells express the same antigen c-erbB-
2, the precise epitope and the specific targeting site may be
different to each other. However, the precise reason for
the reduced efficacy to other breast cancer cell lines
remains to be resolved.
The PMN peptide molecule mainly consists of conlicin Ia
(Fig. 1). The E1 colicin family protein are produced by E.
coli and permanently existed in live beings. And because
of the parasitism of E. coli in intestine, which means this
peptide is an immunological tolerant protein for those
parasitifers. Our bio-safe assessment assays demonstrated
the safety of this novel fusion peptide, showing all the
experimental animals gained body weight during experi-
ments, and no microscopic evidences of metastasis, necro-
sis, inflammation and lymphocyte infiltration were
detected in liver, kidney, intestine, lung and spleen from
groups treated by PMN. Those results suggested the in vivo
bio-safety of the novel peptide could be assured. But the
potential toxicity of the toxin-mimetic conjugated peptide
remains to be investigated before using in human.
Conclusion
The present research confirmed that the novel mimetic
maintained the specificity of the original antibody, and
could guide a functional moiety to the target cell mem-
brane to cause specific cell death without any apparent
adverse effects. Further experiments are needed to study
the efficacy of this novel mimetic therapy; nevertheless the
study provides proof of concept that this novel model of
rebuilding antibody molecules offers additional treat-
ment modalities for targeted therapy of solid tumors.
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Histopathological staining revealed numerous fibrous foci (black arrow) in the tumors from the treated group with PMN (b),  which were not seen in the other control groups (a) Figure 5
Histopathological staining revealed numerous fibrous foci (black arrow) in the tumors from the treated group 
with PMN (b), which were not seen in the other control groups (a). PMN, protomimecin. Scale bar, 50 μm.Publish with BioMed Central    and   every 
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